INmune Bio Inc. INMB Archives - Page 2 of 4

FridayAug 16, 2019 12:31 pm

INmune Bio Inc. (NASDAQ: INMB) Announces Continuous Advancement of Clinical Program, New Strategic Appointment

The immunology company released its financial results for the second quarter of 2019 and also delivered an update on its clinical trials The phase I trial of INmune Bio’s cancer treatment INB03 has delivered promising results in terms of safety and tolerability. The company will now be moving forward with the phase II of the trial INmune Bio also announced the appointment of biotechnology executive Edgardo Baracchini as a new member of the board of directors INmune Bio Inc.’s (NASDAQ: INMB) clinical program continues to advance, CEO RJ Tesi, M.D., noted during a presentation of the company’s 2019 second quarterly…

MondayAug 12, 2019 1:53 pm

QualityStocksNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Releases Q2 2019 Financial Results, Provides Shareholder Update

INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced its financial results for the second quarter ended June 30, 2019 and also provided a year-to-date business update. “This year we remained focused on advancing our pipeline,” INmune Bio CEO RJ Tesi, M.D., said in the news release. “More recently we announced we have begun planning a Phase II trial for INB03 after receiving positive preliminary data from its clinical Phase I study. This preliminary data has allowed us to move forward with the development of…

ThursdayAug 08, 2019 12:06 pm

QualityStocksNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Names Biotechnology Executive as New Board Member

INmune Bio (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that Edgardo “Ed” Baracchini, Ph.D., has joined its board of directors. Per the update, Dr. Baracchini’s impressive biotech business development background includes more than 25 years of experience in structuring and negotiating research and development partnerships, mergers, acquisitions and licensing agreements. He has negotiated over 80 business transactions, valued in excess of $5.3 billion, with multinational pharmaceutical firms, biotechnology companies and prominent universities. “Ed is a fantastic addition to our board of directors,” INmune Bio’s Chief Executive…

WednesdayAug 07, 2019 10:53 am

INmune Bio Inc. (NASDAQ: INMB) Planning Phase II Trial of INB03 as Part of Combination Immunotherapy for Cancer Patients

INmune Bio is currently attending the Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit in Boston Co-founder and CEO Dr. RJ Tesi is presenting positive preliminary data on INB03, which is being developed as part of a combination immunotherapy to potentially reverse resistance to treatment The annual immuno-oncology summit brings together leaders from across the immunotherapy industry and provides unique opportunities to connect scientists with the latest discoveries in the field An international mix of thought leaders and decision makers from the international immunotherapy and immuno-oncology community are gathering in Boston this week, with INmune Bio co-founder and CEO Dr. RJ…

MondayAug 05, 2019 10:20 am

QualityStocksNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Reports Positive Preliminary Data from Phase I Clinical Trial of INB03

INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today reported positive preliminary data during a presentation at Cambridge Healthtech Institute’s Seventh Annual Immuno-Oncology Summit in Boston. Per the update, the company’s INB03 is being developed as part of combination immunotherapy to potentially reverse resistance to treatment. In the open-label, dose-escalation Phase I trial, patients with advanced solid tumors received INB03, a novel, second-generation soluble TNF (tumor necrosis factor) inhibitor that works by a dominant-negative technology. Positive preliminary data from the first two cohorts were released today,…

FridayAug 02, 2019 11:02 am

INmune Bio Inc. (NASDAQ: INMB) Presents Cancer Treatment Immunotherapy at Congress of International Drug Discovery Science & Technology

INmune Bio attended the 17th Annual Congress of International Drug Discovery Science & Technology in Japan Co-founder and CEO R.J. Tesi and Director of Neuroscience C.J. Barnum both participated in talks about the role of immunotherapy in the treatment of specific medical conditions The congress was a paramount event in the field of immunotherapy, allowing researchers to network, exchange ideas and discuss recent developments INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness patients’ innate immune systems to fight disease, presented its innovative cancer immunotherapy, as well as its Alzheimer’s disease drug candidate, during a…

ThursdayAug 01, 2019 12:08 pm

QualityStocksNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Co-Founder and CEO to Present at Cambridge Healthcare Institute’s Seventh Annual Immuno-Oncology Summit

INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, this morning announced that its Co-Founder and CEO RJ Tesi, M.D. will present at the Cambridge Healthcare Institute’s Seventh Annual Immuno-Oncology Summit. The event is taking place in Boston from August 5 through August 9, 2019, and Dr. Tesi’s presentations will include “Targeting Soluble TNF to Improve Efficacy of Combination Immunotherapy,” “Next-Generation Immunotherapies,” and “Targeting ‘Protector’ Cells of the Innate Immune System.” “We are committed to helping treatment-resistant patients by advancing the clinical development of combination therapies and…

MondayJul 29, 2019 11:43 am

Research Highlights Virtues of INmune Bio Inc.’s (NASDAQ: INMB) Strategy in Fighting Cancer with Body’s Own Natural Cells

California-based INmune Bio is developing therapies to battle cancers and Alzheimer’s disease by more effectively engaging the body’s own natural defenses Research published in a peer-reviewed scientific journal shows a mechanism by which scientists can track and strategize natural killer cell promotion as an innate physical response to cancer in lieu of other pharmaceutical inducements INmune Bio’s INKmune product, derived from the cell line used in its research, naturally targets “residual disease” cells that may survive other cancer treatments and revitalize themselves to create a relapse of cancer The battle to marshal naturally occurring cells within the human body to…

ThursdayJul 25, 2019 12:02 pm

QualityStocksNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) to Present at 17th Annual Congress of International Drug Discovery Science & Technology 2019

INmune Bio (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, this morning announced that its Director of Neuroscience, C.J. Barnum, and Co-Founder and CEO, R.J. Tesi, M.D., will present at the 17th Annual Congress of International Drug Discovery Science & Technology. The event, scheduled to take place in Japan on July 26, 2019, brings together immunotherapy industry leaders and provides a unique opportunity to connect scientists and facilitate the exchange of ideas and developments. According to the update, Dr. Tesi’s talk is titled, “Combination Immunotherapy to Overcome Resistance to…

FridayJul 19, 2019 1:18 pm

QualityStocksNewsBreaks – INmune Bio Inc.’s (NASDAQ: INMB) Innovative Drug Candidate Targets Neuroinflammation to Treat Alzheimer’s Disease

INmune Bio (NASDAQ: INMB) is an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, such as Alzheimer’s disease (“AD”). A recent article discussing the company reads, “An association between inflammation and Alzheimer’s disease has long been established. Until present, however, this link and the way in which it could be used to offer reliable AD treatments have both been overlooked. Numerous inflammatory markers are found in AD patients, and several studies establish a link between chronic inflammation and the development of AD. . . . XPro1595 works by targeting the microglial immune…

Site Search

Company Search

Tag: INmune Bio Inc. INMB